Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05371964 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis

A Phase 1 study of Myelofibrosis, sponsored by Geron Corporation.

Recruiting
Registry status
Phase 1
Development phase
36
Enrollment target
8
Study locations

NCT05371964 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by Geron Corporation. The registered enrollment target is 36 participants, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05371964, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by Geron Corporation.

RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
8
Study locations

Study Summary

The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolitinib in participants with MF in Part 2.

Conditions Studied

Myelofibrosis

Interventions

  • DRUG Ruxolitinib
  • DRUG Imetelstat sodium

Study Locations (8)

California

  • City of Hope - Duarte
  • City of Hope - Irvine

Florida

  • University of Miami - Coral Gables
  • H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa

Texas

  • Texas Oncology - Denison
  • Texas Oncology - Tyler

New York

  • Icahn School of Medicine at Mount Sinai - New York

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2022-05-04
Est. Completion 2028-08
Phase Phase 1

Sponsor

Geron Corporation

15 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05371964

The ClinicalTrials.gov registry entry for NCT05371964 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 61 other Myelofibrosis trials with a reported enrollment target (82% lower). The listed sponsor is Geron Corporation, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.

NCT05371964 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT05371964 about?

NCT05371964 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis". The purpose of the study is to identify the recommended Part 2 dose (R2PD) of imetelstat sodium in combination with ruxolitinib in participants with myelofibrosis (MF) in Part 1, and to evaluate the safety and preliminary clinical activity of the R2PD of imetelstat sodium in combination with ruxolit...

What is the current status of trial NCT05371964?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-05-04. Estimated completion is 2028-08.

What conditions does trial NCT05371964 study?

This clinical trial studies the following conditions: Myelofibrosis.

What interventions are being tested in trial NCT05371964?

The interventions under investigation include: Ruxolitinib (DRUG), Imetelstat sodium (DRUG).

Who is sponsoring clinical trial NCT05371964?

This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05371964 being conducted?

This trial has 8 study locations across California, Florida, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myelofibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myelofibrosis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.